Search Results - "Demarest, Stephen J."

Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface by Lewis, Steven M, Wu, Xiufeng, Pustilnik, Anna, Sereno, Arlene, Huang, Flora, Rick, Heather L, Guntas, Gurkan, Leaver-Fay, Andrew, Smith, Eric M, Ho, Carolyn, Hansen-Estruch, Christophe, Chamberlain, Aaron K, Truhlar, Stephanie M, Conner, Elaine M, Atwell, Shane, Kuhlman, Brian, Demarest, Stephen J

“…Bispecifics by orthogonal interfaces To improve correct antibody heavy-light chain pairing during bispecific antibody assembly, Lewis et al. design antibody…”
Get full text

A broad range of Fab stabilities within a host of therapeutic IgGs by Garber, Ellen, Demarest, Stephen J.

“…Although the functional properties of IgGs are well known, little has been published concerning the stability of whole IgG molecules. Stability is, however, a…”
Get full text

Computationally Designed Bispecific Antibodies using Negative State Repertoires by Leaver-Fay, Andrew, Froning, Karen J., Atwell, Shane, Aldaz, Hector, Pustilnik, Anna, Lu, Frances, Huang, Flora, Yuan, Richard, Hassanali, Saleema, Chamberlain, Aaron K., Fitchett, Jonathan R., Demarest, Stephen J., Kuhlman, Brian

“…A challenge in the structure-based design of specificity is modeling the negative states, i.e., the complexes that you do not want to form. This is a difficult…”
Get full text

Engineering a tumor-selective prodrug T-cell engager bispecific antibody for safer immunotherapy by McCue, Amelia C, Demarest, Stephen J, Froning, Karen J, Hickey, Michael J, Antonysamy, Stephen, Kuhlman, Brian

“…T-cell engaging (TCE) bispecific antibodies are potent drugs that trigger the immune system to eliminate cancer cells, but administration can be accompanied by…”
Get full text

Computational stabilization of T cell receptors allows pairing with antibodies to form bispecifics by Froning, Karen, Maguire, Jack, Sereno, Arlene, Huang, Flora, Chang, Shawn, Weichert, Kenneth, Frommelt, Anton J., Dong, Jessica, Wu, Xiufeng, Austin, Heather, Conner, Elaine M., Fitchett, Jonathan R., Heng, Aik Roy, Balasubramaniam, Deepa, Hilgers, Mark T., Kuhlman, Brian, Demarest, Stephen J.

“…Recombinant T cell receptors (TCRs) can be used to redirect naïve T cells to eliminate virally infected or cancerous cells; however, they are plagued by low…”
Get full text

Fine Details of IGF-1R Activation, Inhibition, and Asymmetry Determined by Associated Hydrogen /Deuterium-Exchange and Peptide Mass Mapping by Houde, Damian, Demarest, Stephen J.

“…The structural features of the asymmetric activated states of the insulin receptor family are still poorly understood. We investigated hydrogen/deuterium…”
Get full text

Generalizable design parameters for soluble T cell receptor-based T cell engagers by Froning, Karen J, Sereno, Arlene, Huang, Flora, Demarest, Stephen J

“…While most biological and cellular immunotherapies recognize extracellular targets, T cell receptor (TCR) therapeutics are unique in their ability to recognize…”
Get full text

Stability engineering of scFvs for the development of bispecific and multivalent antibodies by Miller, Brian R., Demarest, Stephen J., Lugovskoy, Alexey, Huang, Flora, Wu, Xiufeng, Snyder, William B., Croner, Lisa J., Wang, Norman, Amatucci, Aldo, Michaelson, Jennifer S., Glaser, Scott M.

“…Single-chain Fvs (scFvs) are commonly used building blocks for creating engineered diagnostic and therapeutic antibody molecules. Bispecific antibodies (BsAbs)…”
Get full text

Mutual synergistic folding in recruitment of CBP/p300 by p160 nuclear receptor coactivators by Wright, Peter E, Demarest, Stephen J, Martinez-Yamout, Maria, Chung, John, Chen, Hongwu, Xu, Wei, Dyson, H. Jane, Evans, Ronald M

“…Nuclear hormone receptors are ligand-activated transcription factors that regulate the expression of genes that are essential for development, reproduction and…”
Get full text

Emerging antibody combinations in oncology by Demarest, Stephen J., Hariharan, Kandasamy, Dong, Jianying

“…The use of monoclonal antibodies (mAbs) has become a general approach for specifically targeting and treating human disease. In oncology, the therapeutic…”
Get full text

Combination of two insulin-like growth factor-I receptor inhibitory antibodies targeting distinct epitopes leads to an enhanced antitumor response by Dong, Jianying, Demarest, Stephen J, Sereno, Arlene, Tamraz, Susan, Langley, Emma, Doern, Adam, Snipas, Tracey, Perron, Keli, Joseph, Ingrid, Glaser, Scott M, Ho, Steffan N, Reff, Mitchell E, Hariharan, Kandasamy

“…The insulin-like growth factor-I receptor (IGF-IR) is a cell surface receptor tyrosine kinase that mediates cell survival signaling and supports tumor…”
Get full text

Building blocks for bispecific and trispecific antibodies by Wu, Xiufeng, Demarest, Stephen J.

“…Bispecific antibodies (BsAbs), which target two antigens or epitopes, incorporate the specificities and properties of two distinct monoclonal antibodies (mAbs)…”
Get full text

Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTβR by Michaelson, Jennifer S., Demarest, Stephen J., Miller, Brian, Amatucci, Aldo, Snyder, William B., Wu, Xiufeng, Huang, Flora, Phan, Samantha, Gao, Sharon, Doern, Adam, Farrington, Graham K., Lugovskoy, Alexey A., Joseph, Ingrid, Bailly, Veronique, Wang, Xin, Garber, Ellen, Browning, Jeff, Glaser, Scott M.

“…Bispecific antibodies (BsAbs) represent an emerging class of biologics that achieve dual targeting with a single agent. Recombinant DNA technologies have…”
Get full text

Conserved amino acid networks involved in antibody variable domain interactions by Wang, Norman, Smith, William F., Miller, Brian R., Aivazian, Dikran, Lugovskoy, Alexey A., Reff, Mitchell E., Glaser, Scott M., Croner, Lisa J., Demarest, Stephen J.

“…Engineered antibodies are a large and growing class of protein therapeutics comprising both marketed products and many molecules in clinical trials in various…”
Get full text

Stable IgG-like Bispecific Antibodies Directed toward the Type I Insulin-like Growth Factor Receptor Demonstrate Enhanced Ligand Blockade and Anti-tumor Activity by Dong, Jianying, Sereno, Arlene, Snyder, William B., Miller, Brian R., Tamraz, Susan, Doern, Adam, Favis, Michael, Wu, Xiufeng, Tran, Hon, Langley, Emma, Joseph, Ingrid, Boccia, Antonio, Kelly, Rebecca, Wortham, Kathleen, Wang, Qin, Berquist, Lisa, Huang, Flora, Gao, Sharon X., Zhang, Ying, Lugovskoy, Alexey, Martin, Shelly, Gouvis, Heather, Berkowitz, Steven, Chiang, Gisela, Reff, Mitchell, Glaser, Scott M., Hariharan, Kandasamy, Demarest, Stephen J.

“…Bispecific antibodies (BsAbs) target multiple epitopes on the same molecular target or different targets. Although interest in BsAbs has persisted for decades,…”
Get full text

A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity by Dong, Jianying, Sereno, Arlene, Aivazian, Dikran, Langley, Emma, Miller, Brian R., Snyder, William B, Chan, Eric, Cantele, Matt, Morena, Ronald, Joseph, Ingrid B.J.K., Boccia, Antonio, Virata, Cyrus, Gamez, James, Yco, Grace, Favis, Michael, Wu, Xiufeng, Graff, Christilyn P., Wang, Qin, Rohde, Ellen, Rennard, Rachel, Berquist, Lisa, Huang, Flora, Zhang, Ying, Gao, Sharon X., Ho, Steffan N., Demarest, Stephen J., Reff, Mitchell E., Hariharan, Kandasamy, Glaser, Scott M.

“…The epidermal growth factor receptor (EGFR) and the type I insulin-like growth factor receptor (IGF-1R) are two cell surface receptor tyrosine kinases known to…”
Get full text

Influence of canonical structure determining residues on antibody affinity and stability by Clark, Louis A., Demarest, Stephen J., Eldredge, John, Jarpe, Matthew B., Li, You, Simon, Ken, van Vlijmen, Herman W.T.

“…A number of light and heavy chain canonical residue core redesigns were made in a therapeutic antibody (AQC2, anti-VLA1) Fab to explore the consequences to…”
Get full text

Neutralization of Clostridium difficile toxin A using antibody combinations by Demarest, Stephen J., Hariharan, Mangala, Elia, Marikka, Salbato, Jared, Jin, Ping, Bird, Colin, Short, Jay M., Kimmel, Bruce E., Dudley, Michael, Woodnutt, Gary, Hansen, Geneviève

“…The pathogenicity of Clostridium difficile (C. difficile) is mediated by the release of two toxins, A and B. Both toxins contain large clusters of repeats…”
Get full text

Generation of orthogonal Fab-based trispecific antibody formats by Wu, Xiufeng, Yuan, Richard, Bacica, Michael, Demarest, Stephen J

“…Abstract The clinical success of monoclonal antibodies to treat diseases across nearly every therapeutic area has spurred advances in bispecific antibody…”
Get full text

Packing, specificity, and mutability at the binding interface between the p160 coactivator and CREB‐binding protein by Demarest, Stephen J., Deechongkit, Songpon, Jane Dyson, H., Evans, Ronald M., Wright, Peter E.

“…Among the most common interaction motifs between nuclear proteins is the recognition of one or more amphipathic helices. In an effort to determine principles…”
Get full text